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Abstract 
 
The failing heart is characterized by changes in its structure, function and metabolism. An 
important part of this negative remodelling process is disturbed myocardial energy 
metabolism. The failing myocardium contains low levels of creatine (Cr), phosphocreatine 
(PCr), adenosine-triphosphate (ATP) and accumulates intracellular lipids. Cr depletion in the 
heart muscle may result in disturbed energy production, transfer and utilisation of chemical 
energy and therefore compromised left ventricular function. The heart depends on exogenous 
lipids for the oxidative production of ATP but it also synthesizes and releases lipids in the 
form of apolipoprotein-B containing lipoproteins (apoB). It has been proposed that apoB may 
be involved in cardioprotection by means of elimination of toxic intracellular lipids. 
The aims of this thesis were:  
 To investigate whether measures of intensive cardiac care applied to rats with acute 
myocardial infarction would reduce mortality in this small animal model. 
 To investigate in vivo the effects of Cr depletion in rats on left ventricular function and 
morphology, energy metabolism, catecholamines and incidence of malignant 
ventricular arrhythmias during acute myocardial infarction. 
 To investigate in vivo the effects of Cr depletion in mice on left ventricular function 
and morphology, energy metabolism and myocardial lipids. 
 To investigate importance of endogenous lipoproteins in the heart for cardiac function, 
morphology and survival in the settings of acute and chronic myocardial infarction. 
 To investigate acute and chronic effects of complete heart block on cardiac function, 
morphology and energy metabolism in a rat model. 
 
Using small animal models (rat and mouse) of chemically-induced Cr depletion we show in 
vivo that myocardial creatine depletion leads to disturbed energy metabolism, left ventricular 
dysfunction, pathologic remodeling and accumulation of intracellular triglycerides. These 
alterations are reversible upon the normalization of the creatine levels suggesting that creatine 
metabolism may be an important target for future pharmacological interventions. We provide 
experimental evidence that the biochemically remodeled heart is prone to malignant 
ventricular arrhythmias and to rapid progression to acute heart failure when subjected to 
myocardial infarction.  
Using transgenic animals we show that myocardial apoB is an important cardioprotective 
system. This biochemical system is activated during ischemia, pathologic remodeling and 
heart failure and may be important for survival in myocardial infarction and heart failure.  
Using a rat model of complete heart block we demonstrate that long-term bradycardia leads to 
development of pronounced eccentric hypertrophy with preserved energy metabolism and no 
signs of heart failure – a possible model for future studies of mechanisms behind the 
beneficial cardiac remodeling. 
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List of abbreviations 
 
2, 3-DPG 2, 3-diphosphoglycerate 
31
P Phosphorous  
apoB  apolipoprotein B 
ADP adenosine-triphosphate 
AGAT L-arginine:glycine amidinotransferase 
AMP adenoseine-diphosphate 
ATP adenosine-triphosphate 
BGP beta-guanidino proprionic acid 
CHB complete heart block 
CHF congestive heart failure 
CK creatine kinase 
CO cardiac output 
Cr creatine 
CrT creatine transporter 
FFA free fatty acids 
FS fractional shortening 
GAA guanidinoacetate 
GAMT S-adenosyl-L-methionine:N-guanidinoacetate 
HEP high energy phosphometabolites 
HPLC high performance liquid chromatography 
ISIS image selected in vivo spectroscopy 
LV left ventricle 
LVDd left ventricular diameter in diastole 
LVDs left ventricular diameter in systole 
LVM left ventricular mass 
LVM/BW left ventricular mass index 
MI myocardial infarction 
MRS magenetic resonance spectroscopy 
MTP microsomal transfer protein 
NMR nuclear magnetic resonance 
PCr phosphocreatine 
PDE phosphodiesters 
Pi
 
inorganic phosphate 
SV  stroke volume 
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Introduction 
 
The syndrome of heart failure 
Myocardial infarction (MI) and congestive heart failure (CHF) are the two leading causes of 
morbidity and mortality in Sweden. In spite of the therapeutical success during recent years 
with new drugs and devices the prognosis for patients with MI and CHF remains poor
1-3
.  
Almost half of all patients hospitalized for the first time with CHF will die within 5 years – a 
survival rate far worse than for most types of cancer. Patients living with CHF endure a worse 
quality of life than those with most other chronic diseases. CHF also imposes a heavy burden 
on health care resources, mainly because of the high costs of hospitalization. Sudden cardiac 
death is the most common cause of death in CHF patients and survivors of MI. Over the past 
decade, the rate of hospitalizations for CHF has almost doubled
4
. The prevalence of CHF is 
expected to double in the next decade mainly as a consequence of ageing population and 
increased survival in acute MI due to improved therapeutic interventions
5-7
. Having this in 
mind, the necessity for development of new therapeutic interventions for patients with CHF 
becomes obvious.  
There are various definitions of congestive heart failure (CHF). Probably the most used 
definition of CHF is the one defined by Eugene Braunwald. According to the definition, CHF 
is a pathophysiological condition where the heart is unable to pump sufficient amounts of 
blood to satisfy the metabolic needs of the tissues and organs of the body.
8
 CHF is a complex 
syndrome and may be elicited by various pathophysiological mechanisms such as ischemic 
heart disease, hypertension, valve disease, myocarditis, autoimmunity, toxins, different 
cardiomyopathies and others.   
 
Cardiac remodeling 
As heart disease progresses towards CHF, the myocardium undergoes profound alterations in 
its structure and function at several levels. As the size of the organ increases and function 
deteriorates, there is gradual transformation from a compensated to a decompensated 
condition during which clinical symptoms of CHF become visible (dyspnea, peripheral 
edema, increased heart rate, decrease in physical activity etc.). The complex process 
responsible for this gradual deterioration leading to development of mechanical (pump 
failure) and electrophysiological dysfunction (arrhythmias) is called pathologic cardiac 
remodeling. It can be defined as the sum of all changes at molecular, cellular and at organ 
level which manifests as change in size, shape and function of the heart. The cardiac cell that 
is most affected by cardiac remodeling is the myocyte although other cells are affected as well 
i.e. fibroblast end endothelial cells
9
.   
Pathologic cardiac remodeling is a consequence of different types of heart disease or injuries. 
The process that is of greatest interest for this thesis is remodeling caused by extensive 
ischemic damage i.e. post-infarction remodelling
9, 10
. The cardiac remodeling after MI begins 
immediately after the injury
11-13
.  During the first hours post-infarction, myocyte death 
(necrosis, apoptosis) causes development of inflammation and edema in the infarcted region 
of the heart. After this initial (inflammatory) phase, the formation of scar tissue (replacement 
fibrosis) continues for up to several months after infarction in the human heart
14
. The process 
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Figure 1 Simplified overview for the most important parts of 
creatine and energy metabolism in the cardiomyocyte. Cr = 
creatine. ER= endoplasmatic reticulum, PCr = phosphocreatine, 
ATP=adenosine triphosphate. See the text for more explanations.  
of scar formation is much faster in rodents (mice, rats) and is completed typically within 2-3 
weeks. Pathologic cardiac remodeling is responsible for development of decompensate CHF 
and its most important clinical consequences, i.e. decreased quality of life and premature 
death
10
. To improve symptoms and increase survival in patients with CHF it is very important 
to find ways to reduce and prevent ventricular remodelling
9, 10
. This could be achieved by 
limiting the infarct (damage) size, reduce or prevent infarct expansion or enhance myocardial 
reparation-regeneration processes. To succeed in this goal in the future we will continue to 
depend on relevant animal models
10
.   
Myocardial energy metabolism 
An integral part of pathologic 
cardiac remodeling is alteration 
in myocardial biochemistry - 
biochemical remodelling
15
. One 
of the most important 
consequences of adverse 
biochemical remodeling is the 
disturbed myocardial energy 
metabolism given the 
importance of chemical energy 
for normal heart function. There 
is large body of evidence to 
support the argument that the 
failing heart is an energy starved 
organ
16, 17
. The energy 
starvation is due to disturbances 
in production, transport and 
utilization of chemical energy 
in form of ATP (adenosine 
triphosphate)
17-19
. At a cellular level, ATP is the energy source for most biological systems. 
The heart has intricate biochemical machinery for production, transport and consumption of 
chemical energy (Figure 1). The ability of the heart to develop a propelling pressure to cause 
the blood to flow in our vessels by its “indefatigable” contractions is a process that requires an 
enormous amount of energy in uninterrupted supply.  Myofibrils use the energy stored in the 
ATP molecule producing degradation products ADP (adenosine-diphosphate) and inorganic 
phosphate (Pi). ATP can be produced in several different ways: de novo synthesis, phosphoryl 
transfer from phosphocreatine (PCr) catalyzed by creatine kinase (CK), oxidative 
phosphorylation of ADP.  For the heart to function normally it is necessary that the 
myocardial ATP is maintained within narrow narrow boundaries of “physiological” 
concentration. The heart has developed a robust “biochemical machinery” in order to fulfill 
this important prerequisite even if the energy demand characteristically varies in the mammal 
heart due to different workload. Myocardial oxygen consumption is directly proportional to 
the rate of the oxygen that is needed for ATP synthesis by oxidative phosphorylation. With 
increasing oxygen consumption due to higher workload, the healthy heart will increase its 
synthesis of ATP in order to match the increased energy demand and maintain [ATP] 
constant.    
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The main energy producing mechanism in the heart is the ATP synthesis by oxidative 
phosphorylation. This takes place in the mitochondria, the respiratory chain, supply of oxygen 
and the ATPase taken together, rephosphorylate ADP into ATP.   
ATP  is required for many essential reactions in the myocytes for 
example; in the myofibrilar cross-bridge ATPase reaction, the Ca
2+ 
-ATPase reaction in the 
endoplasmatic reticulum (ER) and many energy-demanding sodium-potassium pumps in the 
cell membrane. In order to describe the energy state of the cell we need to define relationship 
between energy demand and supply. This can be achieved by providing different biochemical 
indexes such as phosphorylation potential, PCr/ATP ratio, free energy of the of ATP 
hydrolysis and others. Phosphorylation potential is defined as: [ATP]/ [ADP] [Pi]. High 
[ATP]/ [ADP] [Pi] ratios inhibits ATP synthesis and stimulates chemical reactions that use 
ATP as substrate and low [ATP]/ [ADP] [Pi]ratios results in the opposite
20
. In a normal, well 
perfused heart the typical values for ATP, ADP and Pi concentrations are 10mM, 30μM and 
1mM respectively. Even very modest increases in ADP and Pi concentrations at essentially 
constant ATP concentrations results in a huge difference in the phosphorylation potential, thus 
making it a very sensitive marker of the energetic state of the cell
20
. The phosphorylation 
potential has vast influence on the free energy of the of ATP hydrolysis, ΔG~P. The free 
energy of ATP hydrolysis defines the driving force for all ATP utilizing reactions in the cell, 
it is expressed as : ΔG~P = ΔG~P
°
 - RT ln [ATP]/ [ADP] [Pi], where ΔG~P
°
 is the standard free 
energy change of ATP hydrolysis, R is the gas constant and T is the absolute temperature in 
Kelvin. ΔG~P is often described as its absolute value, ׀ΔG~P׀.  For an ATP utilizing reaction to 
take place, the driving force (׀ΔG~P׀) of the cytoplasm of the cell must be greater that the 
threshold value for that particular reaction. One way to describe the difference between 
׀ΔG~P׀ for the cell and the ׀ΔG~P׀ for a specific ATP utilizing reaction is energy reserve
20
. So 
it is important for the cell to maintain high phosphorylation potential and ׀ΔG~P׀.  One way to 
maintain a high phosphorylation potential is via the creatine kinase (CK) reaction.   
The CK reaction rapidly resynthesize ATP by transferring a phosphoryl group from 
phosphocreatine (PCr) to ADP, and thereby it also keeps the [ADP] low
20
.  
ATP utilization: ATP + H2O → ADP + Pi + H
+ 
ATP resupply: PCr + ADP + H
+ ↔ Cr + ATP   
There are different kinds of CK enzymes, the mitochondrial CK (CKmito, which comes in two 
different forms ubiquitous and sarcomeric), the cytosolic M-CK (M = muscle) and B-CK (B = 
brain). The CK enzymes catalyze the reversible transfer of a phosphate group from ATP to 
the guanidine group of creatine (Cr) to yield ADP and PCr
16, 20-22
.   
The presence of one CK enzyme both in the mitochondria and in the cytosol creates a shuttle 
of energy from the mitochondria, where it is produced, to the sites of energy utilization, e.g. 
the myofibrils and ion pumps.  After ATP synthetisation in the mitochondria, a phosphate 
group from ATP is transferred by CK to Cr to produce ADP and phosphocreatine (PCr). The 
ADP released in this reaction is directly transported back and rephosphorylated. PCr on the 
other hand, leaves the mitochondria and diffuses through the cytosol to the sites of ATP 
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consumption. At  these sites, CK enzymes uses PCr to rephosphorylate ADP into ATP after 
which Cr diffuses back to the mitichondria
21
.  
 
Creatine and creatine transporter 
 
Cr  and PCr  are smaller and less negatively charged than 
ATP and ADP. Consequently, they can be stored in a much higher concentrations and can be 
more easily transported to the different sites in the cell
21
.  PCr is therefore considered as the 
main energy storage in the myocyte. Cr can either be introduced by food intake or be 
synthesized in the body. Cr synthesis begins in the kidney with the transfer of the amidino 
group from arginine to glycine which produces guanidinoacetate (GAA) (Figure 2). This 
reaction is catalyzed by L-arginine:glycine amidinotransferase (AGAT). GAA is then 
transported through the blood to the liver where it is methylated to Cr. The methylation step is 
catalyzed by S-adenosyl-L-methionine:N-guanidinoacetatetransferase (GAMT).   The Cr 
leaves the liver and is transported through the bloodstream to tissues that require Cr
21
.  Cr 
uptake from the blood, into tissue that contains CK, as heart, skeletal muscle, brain or kidney 
is enabled by a specific creatine transporter (CrT)
21, 23
. It has been found that the CrT can be 
either up- or down-regulated due to a number of different reasons. One of the consequences of 
CHF is down-regulation of  the CrT in the cell membrane of cardiomyocytes
24
. In 
experimental studies, Cr supplementation lead to down-regulation of creatine transporter both 
in rats
25
 and in cell culture
26, 27.  Cr depletion induced by the creatine analogue, β-
guanidinoproprionic acid (BGP) in rats, lead to an increase in the CrT membrane 
availability
28
. 
 
 
 
Figure 2 Synthesis of creatine. 
Arg - Arginine; AGAT - L-arginine:glycine amidinotransferase; GAMT - Guanidinoacetate N-
methyltransferase; Gly - Glycine; Met - Methionine; SAH - S-adenosyl homocysteine; SAM - S-adenosyl 
methionine. 
AGAT
GAMT
creatine
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Myocardial energy metabolism in the failing heart 
There has been a longstanding and controversial debate on the hypothesis of energy starvation 
of the failing heart
17, 29, 30
. The debate is in part due to the complexity of the cellular and 
molecular alterations in the pathogenesis of heart failure and partly due to limitations in the 
methodology for studying myocardial energetics. Over a long period of time, myocardial ATP 
concentration was considered to be the hallmark of the myocardial energy status.   
The introduction of whole organ NMR spectroscopy was a methodological breakthrough in 
the study of myocardial energetics, gaining new insights in to the field of myocardial 
energetics in the failing heart. 
31
P NMR spectroscopy allows in vitro and in vivo 
measurements of myocardial high energy phosphate content simultaneously with 
measurements of contractile function. This technique allows dynamic measurements of 
reaction velocities of the ATP synthesis pathways.  
Today,  there is compelling evidence, from both clinical and experimental studies, that HF is 
characterized by disturbances in the myocardial energy metabolism
20, 31-34
.  It has been 
previously demonstrated that that disturbances in myocardial energy metabolism ensue early 
in the post-infarct period and that lowering of myocardial energy reserve correlates with 
parameters of LV systolic and diastolic dysfunction, as well as with LV wall stress. Failing 
and hypertrophied myocardium is characterized by several consistent changes in the cellular 
energetic system, regardless of species. The size of the creatine pool is decreased in the failing 
heart. In CHF, the decrease in Cr is cardiac specific
35
, in difference to in creatine deficiency 
syndrome
36
. High energy phosphate metabolites  are decreased in failing
31-33, 35, 37-39
and post-
infarct remodeled hearts
40, 41
 . PCr decreases early in the development of heart failure while 
ATP decrease occurs at the late-stage heart failure
33, 35, 42
.  In many of these experiments, the 
decrease in PCr was larger than the decrease in ATP resulting in lower PCr/ATP ratio. The 
PCr/ATP ratio is a commonly used index of cellular energy status because it reflects the 
equation of cellular phosphorylation potential. The PCr/ATP ratio is clinically very useful as 
it can be measured noninvasively in vivo by means of 
31
P Magnetic resonance spectroscopy 
(MRS)
32, 43, 44
.  The total creatine pool, i.e. the sum of Cr and PCr, is decreased in the failing 
heart
16, 22, 45, 46
. Creatine depletion is now considered a characteristic of the failing heart 
muscle
24, 47-49
. This has been proven in both human
16
 and animal studies
24, 50-52
  Decreases in 
PCr and Cr occurs earlier than decreases in ATP. This could be the result of the heart’s 
attempt to maintain normal free energy of ATP hydrolysis at the cost of decreasing 
intracellular Cr and thereby energy reserve. There is evidence for a decrease in the CK 
activity
31, 34, 53, 54
 which results in compromised capacity of the CK system to rephosphorylate 
ADP into ATP leading to further decrease in the energy reserve. The end-result is an energy 
starved heart
55
. Depletion of the creatine pool can also lead to LV hypertrophy, increased 
propensity for development of malignant arrhythmias and systolic and diastolic dysfunction
56, 
57
.  Down-regulation of CrT in the cell membrane is also a phenomenon found in the failing 
heart
24
. This is probably a negative phenomenon (if sustained over the long period of time) in 
the failing heart. Is the decrease in energy reserve a cause or a consequence of heart 
dysfunction? In recent years there has been numerous experimental studies performed in order 
to answer this question
35, 47, 58-61
.  To study how disturbed myocardial energy metabolism 
affects function and morphology one can use various experimental approaches. A very simple 
in vivo animal model is chemical depletion of the creatine by creatine analogue, BGP.  
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BGP   is an analogue to creatine which can enter the myocyte through the 
creatine transporter
62
 and thereby competitively inhibit Cr from entering the cell from the 
blood stream. Inside the myocyte, BGP can enter the mitochondria in the same way as Cr, and 
is used as a substrate for the CKmito to produce phosphorylated BGP and ADP
63
. But there is 
one major difference of BGP’s function in the myocyte compared to the function of creatine, 
it functions very poorly as a substrate for the cytosolic CK to produce ATP. The activity of 
this reaction is 3 orders of magnitude lower of its activity when using PCr as substrate
64
. This 
effectively inhibits the CK reaction
64
 and creates an ATP deficiency in the myocyte. The 
model mostly used in BGP-induced creatine depletion is by distribution of BGP to the 
animals via food and water supply. The effects of BGP feeding, are similar to what is 
observed in CK-deficient mice
58, 65-67
.  CK deficient mice are only one of several knock-
out/transgenic models used to study the influence of creatine metabolism on the heart. Others 
are GAMT deficient mice
49, 68
, and mice overexpressing CrT
48
. 
 
Lipotoxicity in myocardial infarction and heart failure - importance of endogenous 
lipoproteins for cardiac function, structure and arrhythmias. 
 
The heart is an organ heavily dependent on exogenous lipids for oxidative production of ATP, 
which is essential for maintenance of normal cellular energy homeostasis. During the last 
years surprising data have been reported showing unequivocally that the heart besides being 
dependent on exogenous lipids also synthesizes its own endogenous lipids
69, 70
. These lipids 
are produced and secreted in the form of apoB-containing lipoproteins (apoB) - which are 
structurally much alike plasma low-density lipoprotein particles. This phenomenon has been 
confirmed in several different species including humans. The fact that both humans and mice 
- two species parted by million years of evolution - have preserved the biochemical machinery 
for myocardial production of lipoproteins suggests an important physiological and/or 
pathophysiological regulatory role. What we know from experiments performed in transgenic 
animals supported by human data is that myocardial apoB production is probably not 
important for maintenance of normal cardiac function and structure. Both knock-out mice and 
humans with the rare genetic defect resulting in inability to express MTP (microsomal transfer 
protein – initial step in the synthesis of apoB) and consequently in abetalipoproteinemia, have 
normal cardiac structure and function. What we don’t know is the function of myocardial 
apoB in the heart under pathologic conditions. Myocardial apoB could be an important 
cardioprotective system mobilized during pathophysiological conditions such as ischemia, 
pathologic remodeling and heart failure. These conditions are associated with accumulation of 
intracellular lipids (free fatty acids, triglycerides, ceramides, lysophospholipids etc.) in the 
heart. Excessive accumulation of lipids is damaging to cellular function and structure and 
results in development of lipotoxic heart disease. It has been demonstrated that excessive 
accumulation of lipids in the heart leads to
71-74
:  
 
1. Reduction in mitochondrial electron transfer activity. 
2. Uncoupling of oxidative phosphorylation. 
3. Reduction in activity of ATPases.  
4. Induction of cardiac hypertrophy. 
5. Induction of mitochondrial death and apoptosis. 
6. Systolic and diastolic dysfunction.  
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Our hypothesis is that apoB isolates and exports toxic lipids from cardiomyocytes and 
therefore plays an important role in maintenance of normal membrane function of organelles 
such as mitochondria, sarcoplasmatic reticulum and sarcolemma. Functional disturbance of 
these cellular units results in development of cell death and/or electrophysiological instability. 
In clinical terms these events would translate into development of congestive heart failure 
(CHF), malignant ventricular arrhythmias and sudden death. 
Are endogenous lipoproteins important for preservation of myocardial function, structure and 
survival during MI and CHF?  Intracellular lipotoxicity during MI and CHF causes cell 
dysfunction, cell necrosis and apoptosis. Given the previous statement we propose the 
following hypothesis: The heart has a protective system- apoB - which is mobilized during 
MI and CHF to counteract lipotoxicity by isolating and exporting toxic lipids (FFA, 
triglycerides, oxidized lipoproteins etc). Effective export of intracellular lipids accumulated 
during ischemia is essential for recovery of normal function of sarcolemma and other 
membrane-associated organelles. This improves myocardial function, attenuates pathologic 
remodeling and reduces malignant arrhythmias. 
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Aims of the study 
 
 
 To investigate whether measures of intensive cardiac care applied to rats with acute 
myocardial infarction would reduce mortality rate in this small animal model.  
 
 
 To investigate in vivo the effects of Cr depletion in rats on left ventricular function and 
morphology, energy metabolism, catecholamines and incidence of malignant 
ventricular arrhythmias during acute myocardial infarction. 
 
 
 To investigate in vivo the effects of Cr depletion in mice on left ventricular function 
and morphology, energy metabolism and myocardial lipids. 
 
 
 To investigate the importance of endogenous lipoproteins in the heart for cardiac 
function, morphology and survival in the settings of acute and chronic myocardial 
infarction. 
 
 To investigate acute and chronic effects of complete heart block on cardiac function, 
morphology and energy metabolism in the rat model. 
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Methodological considerations 
 
General descriptions of material and methods are given in each individual paper. In this 
section specific consideration and in some cases more detailed descriptions, of some of the 
methods are discussed. 
  
Myocardial injury models 
The rat model of myocardial infarction is widely used in experimental cardiology for 
preclinical studies. It has been a very valuable tool in this research field because of its 
similarity with the major pathophysiological events occurring in patients with MI and heart 
failure
75, 76
. However, this model has one large disadvantage. In order to induce postinfarction 
heart failure, one needs to create large infarction which results in a high mortality rate.  
In paper I we aimed to address the question if it was possible to lower the mortality rate using 
some of the therapeutical interventions used in the every-day-care of patients in coronary care 
units. So we randomly divided the animals into two groups; the conventional care (CC) group 
and the intensive care (IC) group. The intensive care group was pre-treated with an injection 
of amiodarone to lower the incidence of arrhythmias. The anesthesia used in this group was 
isoflurane instead of injection anesthesia used in the CC group. This enabled us to control the 
grade of anesthesia during the surgery, and allowed for a quick recovery post-surgery. After 
surgery the IC group animals were given continuous respiratory support until they showed 
signs of spontaneous recovery. The IC group was monitored with ECG during the entire 
surgical procedure and during the recovery period. If the animals in the IC group suffered any 
arrhythmias, they were treated with cardioversion using a home-made defibrillator for small 
animals, with delivery of electroshocks in the range of 2-6 Joule.  
 
Induction of myocardial infarction (papers I, II, IV) 
The animals were anesthetized with isoflurane, intubated and connected to a small animal 
ventilator. The animals were kept ventilated and maintained on 2% isoflurane mixed with 
oxygen and room air, all through the operation. Electrodes were placed on the extremities and 
connected to an ECG device in order to observe the cardiac rhythm during surgery. The chest 
was shaved using an electrical clipper. Left thoracotomy was performed between the 4
th
 and 
5
th
 ribs in order to expose the left ventricular wall. The pericardium was removed and the 
branch of the left coronary artery was ligated proximally by positioning a suture between the 
pulmonary artery outflow tract and the left atrium. The efficacy of the procedure was 
immediately verified by characteristic ECG pattern changes, and akinesis of the left 
ventricular wall.  If these changes were not seen, an additional ligature was done. After 
induction of MI was verified, the lungs were hyperinflated, positive end-expiratory pressure 
was applied and the thorax was closed by means of 3-4 sutures. All animals received 
postoperative analgesia with buprenoprin 0.05 mg/kg s.c. and 0.6 mg/100 ml in the drinking 
water and were placed in cages with temperature control for spontaneous recovery. 
 
 METHODS 
17 
 
Ischemia-reperfusion injury (paper IV) 
The animals were anesthetized with isoflurane, intubated and connected to a small animal 
ventilator. The animals were kept ventilated and maintained on 2% isoflurane mixed with 
oxygen and room air, all through the operation until they spontaneously recovered after 
surgery. Electrodes were placed on the extremities and connected to an ECG device in order 
to observe the cardiac rhythm during surgery. The chest was shaved using an electrical 
clipper. Left thoracotomy was performed between the 4
th
 and 5
th
 ribs in order to expose the 
left ventricular wall. After pericardiotomy, a suture was passed under the proximal part of the 
branch of the left coronary artery that corresponds to the LAD in humans. Both ends of this 
suture were then passed through a short plastic tube, by pulling on both ends of the suture the 
plastic tube was gently pressed down on the artery producing a temporary occlusion of the 
vessel. This was verified in the same way as for the permanent MI, by akinesis of the left 
anterior ventricular wall and characteristic ECG changes.  The animals were subjected to 30 
minutes of ischemia and thereafter the vessel was reperfused, the chest was closed, and the 
animals were extubated and placed in temperature controlled cages for recovery.  The animals 
were sacrificed and the hearts were collected at different periods of time after reperfusion. 
  
In vivo 
31
P MRS (paper II) 
Quantitative analysis of high-energy phosphometabolites (HEP) in tissues has been 
traditionally provided with the freeze clamping technique which involves extraction of HEP 
from rapidly frozen tissue samples. High performance liquid chromatography is then used to 
quantify the levels of HEP (PCr, ATP) and inorganic phosphate (Pi) as well as other 
metabolites. This technique is still continuously used in experimental settings. HPLC (High 
performance liquid chromatography)  is regarded as reliable analysis but it is performed on 
tissue samples in vitro and does not allow repeated in vivo investigations of the study object. 
Volume-selective 
31
P MRS is a unique non-invasive tool for in vivo measurements of cellular 
energetic. Using this method, one can produce a 
31
P spectrum that contains information about 
tissue phosphometabolites. Couple of years ago Omerovic et al. were first to establish in vivo 
volume-selective 
31
P MRS in small animals (rats and mice)
77, 78
 using ISIS localization 
method. A typical 
31
P MR spectrum of the normal rat heart is given in the Figure 3. In this 
spectrum one can clearly discern several separate resonance areas. The origin of the 
31
P 
signals are phosphorus containing substances in the myocardium of rat heart obtained in vivo 
at 2.35 T performed at our laboratory. The most prominent resonance is a signal from PCr. To 
the right of PCr there are three resonances that originate from the ,  and  phosphorus 
atoms of ATP molecule. To the left of PCr there are resonances originating from 
phosphodiesters (PDE) and inorganic phosphate (Pi). Spectra obtained in vivo usually contain 
an additional signal close to or overlapping with the signal from Pi. This signal originates 
from blood 2, 3-diphosphoglycerate mainly contained in erythrocytes. Besides concentration 
of phosphorus metabolites, additional information may be derived from 
31
P MR spectrum. 
Since the position of Pi in regard to PCr is dependent on intracellular pH, one can calculate 
intracellular pH in tissue of interest according to the equation. Furthermore, from the 
distance
79
 or the ratio
80
 between - and -ATP resonances one can indirectly calculate the 
intracellular Mg
2+ 
concentration. Another great advantage of the technique is the possibility to 
calculate enzyme kinetics of the creatine kinase reaction using the method of magnetization 
transfer
81-83
, i.e. one can calculate the velocity of the transfer of the phosphate group from PCr 
to ATP and vice versa. For evaluation of the myocardial energy status in vivo it is generally 
 METHODS 
18 
 
Figure 3 
31
P MR spectrum obtained in vivo from the normal rat heart. PCr = 
phosphocreatine; ATP = three 
31
P atoms of the ATP molecule; PDE = phosphodiesters; 
2, 3-DPG = 2, 3-diphoshoglycerate, Pi = inorganic phosphate   
Figure 4 Pacing-induced stress 
echocardiography in the rat model. 
accepted to use different ratios as indicators of energetic state. The two most frequently used 
ratios are, PCr/ATP and PCr/Pi ratios
84-86
. In this thesis we have used PCr/ATP ratio as an 
indicator of myocardial energy status.  
 
 
 
 
 
 
 
 
 
 
 
 
Echocardiography (papers II, III, IV, V) 
We used transthoracal echocardiography for non-
invasive evaluation of cardiac function and 
morphology in rats and mice. The previously 
validated two-dimensional, M-mode and Doppler 
techniques were used. Ventricular function was 
evaluated both during rest and stress conditions. 
Stress was induced either by esophageal pacing 
(Figure 4)
87
 (paper II) or pharmacologically by 
means of dobutamine injection (1μg/g BW) 
(paper III, IV).  The investigations were 
performed with a 15-MHz linear transducer 
connected to a HDI 5000 ultrasound system 
(ATL, Philips Medical Systems). The parameters 
assessed were: left ventricular diameter in diastole 
(LVDd), left ventricular diameter in systole 
(LVDs), fractional shortening (FS), posterior wall 
thickness (PWT), intraventricular septum 
thickness (IVST), relative wall thickness (RWT), 
left ventricular mass (LVM), and left ventricular 
mass index (LVM/BW). LVM was estimated 
using the formula: LVM = 1.05 x [(IVST + LVDd + PWT)
3 – (LVDd)3].  
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Biochemical analysis of creatine and adenine nucleotides (paper II, III, IV) 
The myocardial content of high energy metabolites was of high interest in these studies. Total 
creatine (TCr), which is the sum of Cr and PCr, and total adenine nucleotides (TAN), which is 
the sum of ATP, ADP and AMP, were measured in LV tissue. The reason why we present our 
data as TCr and TAN instead of the respective values for each compound is that the 
breakdown of ATP and PCr in particular, is so rapid that reliable values cannot be obtained 
using biochemical analysis
88
. Since TAN and TCr is the sum of ATP, ADP, AMP and Cr and 
PCr respectively, these values are less sensitive to degradation of ATP and PCr
89
.  Standard 
HPLC  method was used for these measurements. Pieces of freeze-clamped tissue were 
homogenized on ice, in 0.4M perchloric acid. Aliquots of the homogenate were taken for 
protein determination. The rest of the homogenates were neutralized with 1M potassium 
hydroxide, centrifuged for 6 minutes in 5500 rpm at 4° C. Then the supernatants were filtrated 
on ice, using a syringe filter (0,22μm) and thereafter immediately injected into the HPLC 
(Smart system) to be analyzed.  The column used for this analysis was a Luna 5u C18(2) 
column (Phenomenex).  The high energy metabolite content was related to total protein 
content of each sample. The total protein content was determined using a BCA protein assay 
reagent kit.  
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Summary of the results 
Paper I 
Here we wanted to apply standard treatment methods from clinical patient care onto rats in 
order to see if we could decrease the mortality rate in the experimental myocardial infarction 
model.   
Two different clinical outcomes were seen in the animals that died acutely; sudden death due 
to malignant ventricular arrhythmias (MVA) and cardiogenic shock due to progressive heart 
failure. The majority of the animals developed showed signs of some form of MVA within 5 
minutes after occlusion of the coronary artery. The incidence of MVA declined over time. 
The animals in the IC group showed a decrease in the severity and duration of MVA 
compared to the CC group.  Bradycardia was more frequently occurring in the CC group. All 
rats that experienced bradycardia had decreased pulse oximetry values and signs of dyspnea 
which indicated that they suffered from progressive heart failure-cardiogenic shock. The 
mortality rate in these animals were 100%, and interventional treatments, such as continuous 
i.p. infusion of dobutamine or atropine, additional bolus of diuretics, transesophageal pacing, 
and prolonged respiratory support, did not improve their survival.  
Taken together the intensive care methods applied to the rats randomized to the IC group, 
resulted in a 3.5-fold reduction in acute (24 hours) mortality. 
 
Paper II 
An effective way to deplete creatine in experimental models is to use the creatine analogue β-
guanidinoproprionic acid (BGP), previous studies, mostly in vitro, has shown that 
introduction of BGP in the system competitively inhibits Cr from entering the 
cardiomyocytes, thereby reducing myocardial content of total creatine. This inhibits the 
creatine-kinase (CK) reaction and results in compromised systolic and diastolic function. The 
aim of this study was to evaluate the in vivo effects of BGP-induced creatine depletion in rats. 
Furthermore we evaluated the effects of Cr depletion on mortality and occurrence of 
ventricular 
arrhythmias in the 
setting of acute MI. 
We also used a novel 
technique in the 
administration of the 
creatine analogue. 
Traditionally, BGP has 
been administered by 
supplementation in the 
food and water. But 
this is very costly and it 
is also difficult to assess if each animal received the same dose of BGP. We chose instead to 
administer the BGP by means of subcutaneously implanted osmotic minipumps containing 
1M BGP. This subcutaneous delivery of BGP was applied over a period of 4 weeks. No local 
Figure 5  Echocardiographic measurements of left ventricular diameters in 
systole and diastole. There was evidence of LV dilatation and impairment of 
LV function in the BGP group compared to the control group. 
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Figure 7 ECG tracing from a rat with acute MI with 
spontaneously terminating ventricular fibrillation (VF) 
Figure 6 Volume-selective in vivo 
31
P MRS of the rat heart. PCr/ATP 
ratio was reduced by ~40% in the BGP group  
adverse skin effects were found, suggesting good tolerance for this new BGP administration 
technique. 
The results showed that the animals in the BGP treated group had decreased BW and 
increased left ventricular (LV) mass indicating myocardial hypertrophy. LV diameters in 
diastole and systole were increased both during rest and pacing-induced stress in the BGP 
treated animals (Figure 5). LV systolic function measured as FS was disturbed during both 
rest and stress.  In order to evaluate LV energy status the 
animals were investigated with in vivo volume-selective 
31
P MRS. We were unable to calculate PCr/ATP in the 
treated animals due to the overlapping of the resonance 
areas of PCr and phosphorylated BGP (P-BGP) at 
magnetic 2.35 T field strength. However if calculated 
together, the PCr + P-BGP/ATP was decreased by 39% 
compared to controls, which suggests that the PCr/ATP 
was decreased at least by 
~40%, possibly more, in the 
BGP treated group (Figure 6). 
Similar overlapping between 
Cr and BGP and PCr and P-
BGP was seen in the HPLC 
analyses. When calculated 
together, the total Cr was 
reduced by 50% in the BGP 
group. This finding suggests 
that in the BGP treated 
animals, the total creatine 
content in the myocardium 
was decreased by at least 50%.  We found a tendency towards lower myocardial 
noradrenaline (NA) content in BGP group. No difference was observed in the plasma 
catecholamine content.  
As for the effects of creatine depletion in the settings of acute MI, there were two sets of 
clinical courses in the animals that died acutely: Their mode of death was either sudden due to 
ventricular arrhythmias (ventricular fibrillation), or protracted due to progressive heart failure 
and cardiogenic shock characterized by development of sustained bradycardia and severe 
hypoxia. There was a distinct difference in mortality rate between the groups. In the BGP 
treated group 93% of the rats died within 60 minutes post-MI, compared to 46% in the control 
group. There was also a difference in a 
cause of death. In the control group 100% 
of the deaths were due to arrhythmias, 
compared to 78% in the BGP group. The 
remaining 22% of deaths in the BGP 
treated group were due to worsening heart 
failure and cardiogenic shock. The BGP 
treated animals demonstrated a higher 
arrhythmia score suggesting that Cr-
depleted heart is more prone to develop 
malignant ventricular arrhythmias (Figure 
7) during the course of acute myocardial 
infarction.  
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Figure 8 Survival in apoB and wild-type mice after 
myocardial infarction 
Paper III 
Similarly to paper 2 the aim of this study was to investigate the effects of myocardial BGP-
induced creatine depletion on LV function and morphology in mice. We also aimed to 
evaluate effects of creatine depletion on lipid metabolism. Another specific goal was to 
investigate whether alterations in myocardial structure, function and biochemistry were 
reversible upon normalization of the creatine content. The novelty of this study is induction of 
BGP-induced creatine depletion in mice, assessment of lipid metabolism and test of 
reversibility. Similarly to the rat model, after four weeks of BGP treatment the total 
myocardial Cr pool was decreased by 40% compared with controls.  
LV systolic function was decreased in the BGP treated mice. LV dimension both in systole 
and diastole were increased compared with controls, indicating LV dilatation. LV mass was 
also elevated in the BGP treated animals suggesting presence of myocardial hypertrophy.  
There was a 2-fold increase in the myocardial content of triglycerides in the BGP treated 
animals after four weeks. No significant differences were found in the other lipid compounds 
analyzed. Four weeks after discontinuation of the BGP treatment all of these functional, 
morphological and metabolic disturbances (except for the BW) were completely reversed.  
The BW was increased in both groups but was still significantly lower in the BGP treated 
group compared to the control group. 
 
Paper IV 
In this study there were two main aims, 1) to investigate if cardiac apoB-containing 
lipoprotein is activated in response to ischemic injury and doxorubicin (DOX) induced acute 
heart failure and 2) to investigate the effects of apoB overexpression on the myocardial 
function and survival after MI. 
The myocardial apoB content in mice was increased both in the ischemic anterior wall as well 
as in the remote non-ischemic posterior wall, compared with the normal hearts after 0, 3, 6, 24 
and 48 hours of reperfusion following the 30 minutes of ischemia. After 120 hours of 
reperfusion the difference was no longer 
significant compared to the controls. 
There was no difference in apoB content 
between the anterior and posterior wall at 
any of the given time-points of 
reperfusion. Surprisingly, eight weeks 
post-MI, there was a marked decrease in 
apoB content down to 16% of the value 
measured in the controls. No upregulation 
of apoB was detected in the mice with 
DOX-induced acute heart failure.  
An important finding of this study was a 
difference in myocardial response in rats 
compared to mice. This suggests a species 
specific apoB response to myocardial injury. In the rats the apoB content was increased ~2-
fold in the ischemically-damaged part of the myocardium compared to the controls, at 24 
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hours of reperfusion after ischemia, but there was no such increase in the remote non-injured 
region.  Furthermore, DOX-induced heart failure in rats, resulted in a ~70% reduction of 
myocardial apoB content compared to controls. 
Echocardiographic examinations of the heart revealed important differences between the mice 
with apoB overexpression and wild-type mice. The apoB mice had a thinner posteriors wall 
and tended to have a lower heart rate compared to the wild-type mice at baseline. But there 
were no differences in parameters of systolic or diastolic function of left ventricular 
dimensions between the groups, either at rest or during stress conditions. There was no 
difference in LV dimensions between the groups post-MI.  At 2 and 4 weeks post MI the 
apoB mice had better systolic function at rest. This beneficial effect was not sustained at 6 
weeks post MI.  We found no differences in infarct size between the apoB mice and the wild-
type mice at six weeks post MI. BW was similar between the groups at the end of the study. 
However, LV weight was lower in the apoB group. Tthe apoB transgenic mice showed a two-
fold better survival at 6 weeks post MI compared to wild type control mice (Figure 8). The 
largest part of the mortality occurred acute post MI i.e. within the first 24 hours post-
infarction.  
 
Paper V 
The aim of this paper was to study the effects of complete heart block (CHB) on cardiac 
function, morphology, and energy metabolism in a rat model.  At first we tried to induce CHB 
by ethanol injections, but despite increasing amounts of ethanol and repeated injections, the 
success rate for establishment of permanent CHF was as low as 5%.  We changed method and 
started using electrocautery to induce CHB instead. Using this method we were able to 
increase the success rate of permanent CHB induction to 54%. The animals with permanent 
CHB recovered and appeared healthy throughout the course of the experiment. Both short-
term and long-term effects of CHB were evaluated using echocardiography examinations at 1, 
3 and 12 weeks post CHB induction.  The CHB animals had significantly lower ventricular 
rates both at the early and the late time points compared to the controls, but the atrial rates 
were similar between the groups throughout the experiment. LV dimensions were increased in 
the CHB animals compared with the controls and relative LV wall thickness was decreased, 
which suggests development of eccentric hypertrophy. The LV hypertrophy and LV dilation 
was detected as early as 1 week post CHB induction and was sustained until 12 weeks after.  
As a compensation for the lower HR the CHB animals had a 2.5 fold increase in their stroke 
volume (SV), which was sufficient to maintain the CO at similar values as the control 
animals.  The myocardial contractility, seen as FS, was however decreased at 3 and 12 weeks, 
but this was not seen as early as 1 week. The animals were also examined using invasive 
hemodynamics at12 weeks after the CHB induction. There were no differences between the 
groups in left-ventricular and right-ventricular end-diastolic pressures suggesting that CHF 
had not developed in these animals. There were also no signs of disturbed myocardial energy 
metabolism. The myocardial content of creatine and the high-energy phosphometabolites did 
not differ between the groups.  
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Discussion 
 
Paper I 
Scientists and clinicians need to better understand the pathophysiology and molecular 
mechanism of the disease processes involved in development of MI and CHF to define the 
targets for future interventions in order to e.g. decrease MI size, prevent or suppress malignant 
arrhythmias, prevent or attenuate pathologic LV remodeling, improve function and 
morphology of the failing heart etc. To achieve these goals, we will continue to depend on 
relevant animal models. One such valuable model is experimental MI in rats.      
Induction of MI and development of CHF that follows in rats is a widely used experimental 
model for studies of various aspects of MI and CHF. Complete occlusion of the left coronary 
artery results in MI of variable sizes with occurrence of overt heart failure in a subset of 
animals with large MI
78, 90-92
. The impairment of LV function is related to the loss of 
functional myocardium. Development of CHF is associated with LV dilatation, reduced 
systolic function and increased filling pressures as well as with neurohormonal activation 
similar to that seen in patients
90, 93-95
. Besides a large body of knowledge derived from this 
model in terms of basic science and clinical aspects of MI and CHF the model is also 
associated with lower costs for experimental procedures and animal handling as compared to 
the equivalent large animal models. On the other hand, the major disadvantage is high 
mortality particularly in the setting of a large MI which presence is necessary to commence 
the process of LV remodeling. In this study we have demonstrated that malignant ventricular 
arrhythmias (ventricular tachycardia and ventricular fibrillation) and progressive HF are the 
major causes of death. Ventricular arrhythmias were responsible for ~ 80 % of all deaths 
while progressive HF-cardiogenic shock developed in the minority (~ 20%) of the rats. Other 
possible causes of death (usually accidental) include bleeding, infection, excessive inadvertent 
overdosage of anesthesia and drugs. Acute mortality (i.e. within first 24 hours) is responsible 
for ~ 95 % of all deaths that will occur within first 3 months after induction of MI. When 
performing animal experiments one is obliged to follow the laws regulating the use of animals 
for experimental purposes based on the rules stipulated by national and international ethical 
comities. We believe that the use of animals in medical research is not only valuable 
scientifically but is also an ethical imperative prior to clinical trials. However we also support 
the argument that we must improve and develop experimental models which will lead to a 
decrease in unnecessary loss of animal life
96, 97
.          
In conclusion, the study has shown that the use of pre-treatment with the antiarrhythmic drug 
amiodarone, respiratory support, isoflurane gas anaesthesia and aggressive treatment of 
sustained MVA with electrical cardioversion are simple and effective measures which reduce 
mortality in rats with acute MI. Improving survival rates increases ethical acceptance and 
cost-efficiency of this important experimental model.  
 
 
Paper II 
The most important results of this study showed that myocardial Cr depletion results in 
disturbed LV function, pathologic LV remodeling, and altered energy metabolism. Induction 
of acute MI in the setting of creatine depletion is associated with high acute mortality caused 
by ventricular arrhythmias and worsening heart failure.  Our results support the hypothesis 
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that intact myocardial energy metabolism is necessary for maintenance of normal structure 
and function of the heart.  
The rat model of myocardial creatine depletion induced by BGP feeding has been described 
perviously
55
.  Here, however, osmotic minipumps were used for BGP delivery because we 
found it to be more convenient and much less expensive than the food enrichment protocols 
used in previous studies
56, 61, 98
.  
We found that the LV function was deteriorated under both basal and stress conditions. This 
differs from the result in a previous study
55
 in which Cr depletion resulted in LV hypertrophy 
and dysfunction during stress. The reason for this discrepancy between the studies is not clear, 
but could be due to the use of different methods and possibly to a more severe Cr depletion 
using subcutaneous BGP administration. 
Even though it is known that the failing heart is characterized by disturbed energy 
metbolism
20
, it is not yet known to which extent the supply and demand mismatch  in 
chemical energy, contributes to the development of CHF. Our study provides in vivo 
evidence, that Cr depletion may be a part in the pathogenesis of LV dysfunction, pathologic 
remodeling, and disturbed energy metabolism, as seen in CHF patients.  
Others have reported increased LV mass and volume after prolonged BGP feeding
56
. In our 
study we saw evidence of pathologic remodeling already after 4 weeks of BGP treatment, 
using noninvasive in vivo echocardiographic measurements. This confirms the previous 
findings. From the present data we have not been able to determine a cause for the LV 
dilatation, but there are a number of possible explanations. The heart could be trying to 
preserve cardiac output by compensating for the disturbed function, by employing the Frank-
Starling mechanism. Others have implicated Cr in regulation of protein synthesis
99
, if so, 
maybe the LV dilatation could be a direct consequence of the Cr depletion.  
The 
31
P MRS examinations showed a decreased PCr + P-BGP/ATP ratio in the BGP treated 
animals. This is the first in vivo evidence of disturbed energy metabolism in the BGP induced 
Cr depletion. 
A major cause of CHF is ischemic heart disease
2
. A large portion of CHF patients, suffer 
sudden death mostly caused by malignant ventricular arrhythmias
100
. The more advanced the 
CHF is, the higher the mortality rate, and with that the rate of sudden death
101
. Trying to 
decrease this fatal clinical outcome the search for novel therapies and pharmacologic 
interventions is of great importance.  Based on the evidence found in this study, one way to 
achieve this goal may be to prevent Cr depletion and improve the energy metabolism of the 
heart.  In a similar model, others have reported that rats suffering from Cr depletion die within 
24 hours post MI induction
56
, however they did not determine the cause of these deaths.  Our 
data shows that the major causes of death are ventricular arrhythmias, worsening HF and 
cardiogenic shock. This demonstrates that electrophysiological instability is an important 
consequence of disturbed myocardial energy metabolism. An intact Cr metabolism appears to 
be essential for survival during the acute phase of MI. Even though our data in this study does 
not explain the molecular mechanisms behind the increased susceptibility for arrhythmias in 
the energetically altered heart, there is other evidence that support this coupling
102, 103
. But 
other mechanisms may also be involved in the development of ventricular arrhythmias in the 
Cr-depleted heart. There is a possibility that the left ventricular hypertrophy of the Cr-
depleted heart may have contributed to the increased incidence of ventricular arrhythmias. 
Evidence suggest that there is a link between left ventricular hypertrophy and increased 
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incidence of ventricular arrhythmias
104
. However, the sole presence of  left ventricular 
hypertrophy does not always lead to an increased incidence of arrhythmias
105
.  A possible 
direct pro-arrhythmic effect of BGP itself cannot be excluded.  
The absence of data concerning MI size is an important limitation of this study, because it is 
not known how a decrease in myocardial Cr affects MI size. Bothe the severity of left 
ventricular dysfunction and the incidence of ventricular arrhythmias may be dependent on MI 
size. This should be examined in future research. 
In a recent study it was shown also supranormal levels of Cr in the heart may result in left 
ventricular hypertrophy and dysfunction
48
. This provides a strong indication that it is very 
important for the heart to maintain the narrow physiologic Cr concentrations in order to 
uphold normal structure, function and energy metabolism. Further studies should address the 
question of whether disturbances in left ventricular morphology and function caused by CR 
depletion, may be a reversible process.  
 
Paper III 
In this study the aim was to use the same Cr depletion model established in paper II, but in a 
mice model instead, and see if the disturbances in LV function, morphology and creatine 
metabolism was reversible after normalization of the Cr levels. We also wanted to investigate 
if Cr depletion leads to alterations in myocardial lipid metabolism.  
The most important findings of this study is 1) that Cr depletion in mice results in 
compromised cardiac function, development of pathologic LV remodeling and accumulation 
of intracellular triglycerides, and 2) that normalization of the myocardial Cr levels results in a 
complete reversal of these cardiac abnormalities.  
In paper II we found evidence of disturbances in LV function, morphology and energy 
metabolism caused by Cr depletion in a rat model. Those findings are similar to those found 
in this mice model of Cr depletion, in regards to compromised LV function, geometry and 
disturbed energy metabolism.  
In this study we also wanted to investigate, the simple but highly important question whether 
the functional, morphological and metabolic consequences of the Cr depletion were 
reversible. This important question has not been previously addressed. Cr depletion and 
disturbances in the myocardial energy metabolism are generally regarded as a characteristic 
part of the pathological remodeling in CHF. However there are some researchers that argue 
that Cr depletion may be a compensatory biochemical mechanism activated to preserve the 
normal value of ΔG of ATP hydrolysis, and that any measures to increase Cr in the failing 
heart may be deleterious 
16, 20, 50
. Our data speaks against this argument since the spontaneous 
normalization of Cr, following the cessation of BGP treatment, lead to complete reversal of 
the pathologic remodeling with normalization of cardiac function and metabolism. These 
findings support the theory that Cr metabolism could be an important pharmacologic target 
for future CHF therapies.  
Conditions as ischemia, pathologic remodeling and heart failure are associated with 
myocardial accumulation of intracellular lipids. Excessive lipid accumulation in the heart is 
damaging to the cellular function and structure, and leads to the development of lipotoxic 
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heart disease
74
. It is believed that lipotoxicity may significantly contribute to the development 
and progression of CHF. Our study demonstrates that left ventricular dysfunction and 
pathologic remodeling induced by Cr depletion is sufficient to give rise to pronounced 
intracellular accumulation of triglycerides. It is possible that the triglyceride accumulation 
itself contributed to the developed abnormalities in LV function and structure. The 
discontinuation of BGP followed by normalization of the Cr levels in the heart, lead to a 
complete normalization of both triglyceride levels and LV function and morphology. The 
study provides the evidence for an interaction between Cr and TG metabolism. The 
mechanisms behind this is not clear, but some previous studies have demonstrated that Cr is 
directly involved in the regulation of mitochondrial function, which is mediated by a direct 
stimulatory effect of Cr on Krebs cycle and mitochondrial respiration
21, 106
. The Cr depletion 
in this model reduces the stimulatory effect on mitochondria. This may cause decreased fatty-
acid utilization, which in turn could lead to triglyceride accumulation. The hypothesis that Cr 
may play a role in the regulation of mitochondrial function is supported by the existence of a 
specific mitochondrial CrT and a mitochondrial Cr/PCr pool. 
23
. Future studies should look 
into the mechanisms behind the coupling between Cr depletion and triglyceride accumulation.  
Transgenic models of both the depletion of myocardial creatine
49
 and the excess of creatine
48
 
have been reported. These models have contributed to our knowledge of the creatine system 
and its role in myocardial energy metabolism, but they also have limitations. For example the 
knocking of GAMT resulted in decreased Cr levels in both serum and heart, but had no 
obvious effect on the structure and morphology of the heart. These results are in conflict with 
the result from both this study and our previous study in rat (paper II) using the BGP induced 
Cr depletion. The differences could be explained by the fact that in the genetically altered 
animal model, there could be other biochemical mechanisms activated to compensate for the 
faulty metabolic pathway.  
 
Paper IV 
The most important findings in this study are the biphasic pattern of the myocardial apoB 
response, the attenuated/reduced response in DOX-induced acute HF and the marked decrease 
in mortality following MI in mice with apoB overexpression.  
The apoB system may play an important role in the cardioprotection by counteracting 
excessive intracellular lipid accumulation and thereby prevent/attenuate development of 
lipotoxic heart disease
107, 108
. This hypothesis is based on the results from transgenic models 
of myocardial lipotoxicity and development of cardiomyopathic HF. When these transgenic 
mice were crossed with mice that overexpressed apoB in the heart, the result was improved 
cardiac function and survival
107
.  
Our aim was to investigate how myocardial apoB expression affects survival, normal cardiac 
function and structure, and ventricular arrhythmias, in a model of acute MI and HF. This has 
not been studied previously.  
Increased microsomal transfer protein (MTP) expression was found in the hypoxic areas of 
the LV of patients with ischemic heart disease undergoing cardiac surgery, and the MTP 
expression was negatively correlated with TG content
108
. Our results are in agreement with 
these data from the clinical study. We show that ischemia induce a rapid and sustained 
response in apoB expression in the early post-MI phase. The apoB response to an ischemic 
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injury seems to be species specific. In mice we observed up-regulation of apoB in the 
ischemic area but also in the non-ischemic remote area of the heart whereas in rats apoB was 
only up-regulated in the ischemic region. Other studies have  shown that lipids accumulate 
rapidly in the peri-infarct area as well as in the remote, viable myocardium post-MI
109
. The 
reason for the species difference in apoB response is not known, but it may be related to 
known species-dependent differences in the myocardial metabolism
110, 111
.  
An unexpected finding was that apoB dramatically decreased in the hearts of animals with 
chronic post-MI HF. The mechanisms for  this time-dependent difference in the apoB 
response is not clear. We have not measured the apoB expression between five days and eight 
weeks, but it is plausible to assume that the initial increase in the apoB response reaches a 
plateau a few days postinfarction, and then steadily decreases to the subnormal levels found 
eight weeks post-MI. This suggests a development of exhaustion in the apoB response. These 
findings are in agreement with the functional and mortality data from our substudy of survival 
postinfarction in apoB transgenic mice. The excessive mortality in the control group was most 
notable within the first 24h post-MI. This is the phase that shows upregulation of apoB ~2 
times the normal level. This early postinfarction phase is also characterized by development 
of acute HF due to a large MI. The reasons and mechanisms behind the improved survival of 
the apoB overexpressing mice may not be determined by the present data and needs further 
investigation. However, we speculate that myocardial overexpression of apoB results in a 
better and more prompt activation of a compensatory mechanism to maintain contractile 
function. Furthermore, the overexpression of apoB may give rise to mechanisms that protects 
the heart against arrhythmias, by isolating and exporting pro-arrhythmic lipids during and 
after an ischemia-reperfusion period
112, 113
. Although intracellular lipid accumulation has been 
shown to exert pronounced pro-arrhythmic effects
114, 115
 we did not observe any difference in 
arrhythmia incidence between the groups within 45 min post-MI. But we believe that this 
finding should be interpreted cautiously since mice has a low incidence of arrhythmias in the 
setting of MI, compared to other animal models
116, 117
.  There are also differences in regards to 
arrhythmias between different mouse strains
118
. Future studies using other models should 
address the question whether apoB could provide an anti-arrhythmic protection. The fact that 
the incidence of arrhythmias was no different between the groups and that the systolic 
function early post-MI was better in the mice overexpressing apoB, strongly suggests that the 
reason for the increased survival of the apoB mice is related to a better ability to cope with the 
hemodynamic consequences of acute HF. One explanation could be that apoB overexpressing 
hearts are remodeled in terms of function, structure and biochemistry, and that these 
alterations together provide a better ability to adapt during life-threatening conditions such as 
large MI and acute CHF. Further studies are needed to find the mechanisms for these and/or 
other possible differences in the cardiac phenotype of apoB overexpression.  
There was no apparent effect of apoB overexpression on infarct size measured six weeks post-
MI. That the infarct size was similar, but the heart weight was lower indicates an anti-
remodeling effect of apoB.  Previous studies have shown that there is a close relationship 
between myocardial lipid metabolism and hypertrophy
119-121
.  In the late post-MI phase there 
was no longer any improvement in systolic function between the groups, but the survival 
benefit remained however. One could speculate that this may be related to the biphasic time-
dependent apoB response. Exhaustion of apoB maybe a part of a pathologic biochemical 
remodeling, that contributes to the phenomenon of transition from compensated LV 
dysfunction to overt HF. 
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The regulation of apoB synthesis in the liver is relatively well studied
122
, but the regulation of 
endogenous apoB in the heart is more unknown. It is possible that the mechanisms in the heart 
are similar to those in liver. Given the fact that neurohormonal, mechanical and metabolic 
processes are of great importance for the cardiac function and structure after injury, it will be 
important to explore how these processes affect the apoB regulation in the heart post-MI and 
in HF. It should also be explored how myocardial apoB regulation is affected by 
pharmacological agents used for treating MI and HF.  
The finding that doxorubicin-induced acute HF did not induce myocardial apoB synthesis in 
mice and was actually decreased in the rat heart is rather intriguing. It suggests that the 
mechanisms of myocardial damage and/or the nature of the noxious stimuli may be important 
for apoB activation. Doxorubicin -induced cardiotoxicity is a well described model of 
experimental CHF
123, 124
.This agent induces myocardial injury through several mechanisms 
including severe mitochondrial dysfunction, disturbed energy metabolism, lipid accumulation 
and DNA damage (for review see 
125, 126
. We should explore the possibility that doxorubicin - 
due to the DNA damage - may disrupt the genetic message involved in the synthesis of MTP 
and apoB molecules. Indeed, doxorubicin although being one of the most effective cytostatic 
agents for treatment of different malignancies, may cause a special form of toxic 
cardiomyopathy and CHF
127, 128
. This leads to the question whether doxorubicin -induced 
cardiomyopathy at least in part may be mediated by its ability to suppress the apoB response. 
 
Paper V  
The most important results in this study was that induction of complete heart block (CHB) in 
rats resulted in early and sustained cardiac remodeling. The animals with CHB developed 
eccentric LV hypertrophy but have preserved normal systolic function. No evidence of 
disturbed myocardial Cr metabolism was found. 
Animal models of CHB can provide valuable information about the hemodynamic, 
electrophysiological, morphological and metabolic consequences of ventricular bradycardia 
and loss of synchrony between the atrial and ventricular activation. There are several 
experimental models both in large
129, 130
 and small animals
131, 132
. In a rat model recently 
described the CHB was induced by injection of ethanol into the AV-node area
131
.  We were 
unsuccessful in our attempt to reproduce this previous method for induction of permanent 
CHB. Most of the animals developed CHB rapidly upon the injections but the state was 
transient for the most part, only ~5% of the animals developed permanent CHB. We then tried 
direct electrocautery instead and found that to be a much more reliable model for induction of 
CHB.   
The use of echocardiography for non-invasive and longitudinal evaluation of the CHB rat 
model has not been done previously. This investigation revealed important information about 
the LV remodeling and LV function in the rat suffering from CHB. After 1 week post CHB, 
there was already a marked decrease in LV diameters and SV - compensatory mechanisms to 
maintain a normal cardiac output. The animals had developed eccentric hypertrophy, but 
showed no signs of disturbed LV function. The remodeling continued and the eccentric 
hypertrophy increased further during the following weeks. At 3 and 12 weeks the LV 
contractile function, measured as FS, was decreased but no evidence of increasing RV and LV 
filling pressures were found. Decreased FS has not been reported previously in the 
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experimental model of CHB. We speculate that it may be explained by the “Bodwitch-
phenomenon”.  This is a force-frequency relationship that could be explained shortly as; the 
myocardial contractility decreases when HR decreases and vice versa
133, 134
. This hypothesis 
is supported by human data from elite athletes in whom a decreased FS has been 
demonstrated when compared to healthy controls
135, 136
.  
Intracellular depletion of Cr and alterations in the high energy phosphometabolites are 
important indicators of disturbed energy metabolism in the heart. Disturbances in the 
myocardial energy metabolism in general and Cr depletion in particular, have been associated 
with pathologic biochemical remodeling in different types of LV hypertrophy and CHF
28, 47
.  
However, we were unable to detect any signs of disturbances in this system after 12 weeks of 
chronic volume-overload due to complete AV-block, even though the animals now had 
developed pronounced hypertrophy. Other studies have shown a decreased PCr/ATP ratio in 
the failing and hypertrophied heart
20, 50, 51
. Cr depletion is regarded as the major cause for 
decreased PCr content in the myocardium, since 70% of all Cr exists in its phosphorylated 
form, in the setting of chronic CHF and advanced hypertrophy. Therefore it is likely to 
assume that if Cr content is unaltered, the PCr/ATP ratio is also normal.  The reason that our 
data differ from previous reports where hypertrophy is associated with disturbed energy 
metabolism
137, 138
, could be that the eccentric LV hypertrophy associated with chronic CHB is 
more adaptive and physiologic than hypertrophy associated with pure volume-overload.  
Cardiac remodeling is a continuous process of alterations in genome expression, molecular, 
cellular and interstitial changes that are manifested clinically as changes in size, shape and 
function of the heart
9
. The process is influenced by hemodynamic load, neurohormonal 
activation, extent and location of myocardial damage and probably many other factors which 
are currently the focus of clinical and experimental research
139-141
. Cardiac remodeling 
ultimately leads to development of progressive myocardial dysfunction
 
during time. It is 
generally accepted that early remodeling in response to pathologic stimuli (e.g., abnormal
 
wall 
stresses) is an adaptive and useful response in the short term but it is the continuation of the 
process that is regarded as a maladaptive response. This small-animal model of post – CHB 
remodeling offers the possibility to study neurohormonal, metabolic, cellular, subcellular and 
other processes involved in development of adaptive and more physiological LV remodeling 
in contrast to the pathologic remodeling. Insights into molecular mechanisms behind 
beneficial cardiac remodeling may be useful for development of pharmacological and other 
interventions to attenuate and prevent progression of pathologic cardiac remodeling that leads 
to development of CHF. Our findings on LV remodeling and functional adaptation in this 
model are in agreement with those described in the canine model
129, 142
. One important 
limitation of this small animal model of CHB at the present time is a difficulty to implement 
different pacing strategies. This type of studies is more appropriate in large-animal models 
although the future advances in pace-maker technology with development of smaller devices 
may allow pacing studies even in small- animal models.  
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Conclusions 
 
Application of measures of intensive cardiac care effectively decreases mortality in the rat 
model of myocardial infarction and acute heart failure. 
Myocardial creatine depletion leads to disturbed energy metabolism, left ventricular 
dysfunction, pathologic remodeling and accumulation of triglycerides. These alterations are 
reversible upon the normalization of the creatine levels suggesting that creatine metabolism 
may be an important target for future pharmacological intervention in order to increase 
myocardial efficiency and maintain structural integrity of the failing heart. The biochemically 
remodeled heart is extremely prone to malignant ventricular arrhythmias and to rapid 
progression of acute heart failure when subjected to acute myocardial infarction.  
The myocardial apoB could be an important cardioprotective system mobilized during 
pathophysiological conditions such as ischemia, pathologic remodeling and heart failure 
which may protect the heart from pathologic consequences of intracellular lipotoxicity. 
Myocardial apoB system may be involved in the development of doxorubicin-induced 
cardiomyopathy. 
Long-term bradycardia due to complete heart block leads to left ventricular remodeling with 
development of pronounced eccentric hypertrophy but with preserved energy metabolism and 
no signs of heart failure. This model may be useful in future studies of mechanisms behind the 
beneficial cardiac remodeling. 
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